Is Sertraline safe during pregnancy?

Pregnancy category and evidence

Sertraline is among the most-studied SSRIs in pregnancy. Under the former FDA system it was Category C (moved from D back to C after accumulating evidence). Large Scandinavian and US cohort studies (cumulatively >100,000 pregnancies) show no significant increase in major malformations with sertraline. ACOG and NICE both consider it a preferred SSRI when treatment is needed during pregnancy.

By trimester

• First trimester (weeks 1–12): overall rates of major congenital malformations in sertraline-exposed pregnancies are similar to background (~3%). Early signal about cardiac defects from some studies has not been confirmed in larger datasets.
• Second trimester (13–27): generally considered safe. Maintain the minimum effective dose.
• Third trimester (28–40): ~30% of SSRI-exposed neonates experience Poor Neonatal Adaptation Syndrome (jitteriness, feeding difficulty, mild respiratory symptoms) — self-limited, usually resolves in 2–4 weeks. A small increased risk of Persistent Pulmonary Hypertension of the Newborn (PPHN) — absolute risk remains <1%.

Safer alternatives

Sertraline is already one of the preferred SSRIs. If a switch is needed, citalopram or escitalopram are alternatives with similar pregnancy safety profiles. Paroxetine is relatively contraindicated in first trimester due to higher cardiac malformation signal. SNRIs (venlafaxine, duloxetine) have less data.

When it's acceptable and when to be cautious

• Acceptable: maintaining sertraline through pregnancy for moderate-to-severe depression, panic disorder, PTSD — untreated maternal depression carries its own risks (preterm birth, low birth weight, poor maternal outcomes, postpartum depression).
• Cautious discussion needed: mild depression that might respond to CBT alone; planning conception on paroxetine (switch first).